Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Because pituitary corticotroph adenomas express somatostatin receptors, somatostatin analogues have been investigated as a potential targeted therapy for the treatment of Cushing's disease.

Molecular imaging, including somatostatin receptor scintigraphy but more so PET with specific tracers, such as C 11-5HTP or Ga 68-DOTA octreotate, will improve staging and follow-up of therapy in ...

Supplemental BLA accepted for review Paltusotine (Crinetics Pharmaceuticals) Somatostatin receptor type 2 agonist Treatment and long-term maintenance of acromegaly in adults. NDA accepted for ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment ...